SEC Comment Letter 0000000000-25-000669 to MAIA Biotechnology, Inc. (MAIA) (CIK 0001878313) (MAIA)
MAIA Biotechnology, Inc. (MAIA) (CIK 0001878313)
Date: Jan. 22, 2025 · CIK: 0001878313 · Accession: 0000000000-25-000669
AI Filing Summary & Sentiment
Letter
January 22, 2025 Louie Ngar Yee Reporting Person MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 Chicago, IL 60606 Re:MAIA Biotechnology, Inc. Schedule 13D Filed by Louie Ngar Yee Filed October 25, 2024 File No. 005-93731 Dear Louie Ngar Yee: We have conducted a limited review of the above-captioned filing and have the following comment . Please respond to this letter by amending the filing or by providing the requested information. If you do not believe our comment applies to your facts and circumstances or that an amendment is appropriate , please advise us why in a response letter. After reviewing any amendment to the filing and any information provided in response to this comment, we may have additional comments. Schedule 13D Filed October 25, 2024 General 1.We note that the event reported as requiring the filing of the Schedule 13D was March 14, 2024. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule 13D within five business days after the date beneficial ownership of more than five percent of a class of equity securities specified in Rule 13d-1(i)(1) was acquired. Based on the March 14, 2024 event date, the Schedule 13D submitted on October 25, 2024 was not timely filed. Please advise us why the Schedule 13D was not filed within the required five business days after the date of the acquisition. We remind you that the filing person is responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
January 22, 2025 Page 2 Please direct any questions to Brian Soares at 202-551-3690 or Nicholas Panos at 202-551-3266. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions
Show Raw Text
January 22, 2025
Louie Ngar Yee
Reporting Person
MAIA Biotechnology, Inc.
444 West Lake Street, Suite 1700
Chicago, IL 60606
Re:MAIA Biotechnology, Inc.
Schedule 13D Filed by Louie Ngar Yee
Filed October 25, 2024
File No. 005-93731
Dear Louie Ngar Yee:
We have conducted a limited review of the above-captioned filing and have the
following comment .
Please respond to this letter by amending the filing or by providing the requested
information. If you do not believe our comment applies to your facts and circumstances or
that an amendment is appropriate , please advise us why in a response letter.
After reviewing any amendment to the filing and any information provided in
response to this comment, we may have additional comments.
Schedule 13D Filed October 25, 2024
General
1.We note that the event reported as requiring the filing of the Schedule 13D was March
14, 2024. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule 13D
within five business days after the date beneficial ownership of more than five percent
of a class of equity securities specified in Rule 13d-1(i)(1) was acquired. Based on the
March 14, 2024 event date, the Schedule 13D submitted on October 25, 2024 was not
timely filed. Please advise us why the Schedule 13D was not filed within the required
five business days after the date of the acquisition.
We remind you that the filing person is responsible for the accuracy and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of action by the
staff.
January 22, 2025
Page 2
Please direct any questions to Brian Soares at 202-551-3690 or Nicholas Panos at
202-551-3266.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions